Product Highlight - Talzenna

13 Sep 2022
Product Highlight - Talzenna
• Talzenna provides patients a convenient and once-daily oral dosing. For patients who require dose modification, Talzenna offers flexible dosing options.
• Talzenna is proven superior to chemotherapy in delaying disease progression, provides patients with greater efficacy.
• Talzenna offers proven safety and tolerability profile. The most common hematologic adverse reactions to Talzenna were transient and 96.4% of patients did not discontinue Talzenna due to an adverse reaction.

References:
1.Talzenna Approved Malaysia Prescribing Information LPD dated 12 NOV 2021

Related MIMS Drugs

Editor's Recommendations